One E-Commerce Corp (ISLT) 0.2000 $ISLT
Islet Sciences, Inc. Publishes Data Supporting Remogliflozin Etabonate as a Potential Treatment for NAFLD and NASH
GlobeNewswire - Mon May 04, 6:47AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, has announced publication of pre-clinical data that demonstrates remogliflozin etabonate has significant potential as a novel therapeutic for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Islet Sciences, Inc. Presented at 50th International Liver Conference
GlobeNewswire - Thu Apr 23, 11:02AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced today that Chief Operating Officer, Dr. William Wilkison presented "Remogliflozin Etabonate Reduces Insulin Resistance and Liver Function Enzymes: Role for Treatment of NASH" at the 50th International Liver Conference hosted by the European Association for the Study of Liver (EASL) in Vienna, Austria.
Islet Holdings, Inc. Continues With Pursuing Damages in Federal Court
GlobeNewswire - Thu Mar 26, 7:11AM CDT
Islet Holdings, Inc. (OTC:ISHI) ("the Company"
previously announced that in August 2012, the Company and its subsidiary filed a complaint in Federal District Court for the District of Utah against Islet Sciences, Inc., a publicly-held company trading under the symbol "ISLT", and several individuals intimately involved with Islet Sciences. The complaint is related to the Company's prior work and development in the type 1 diabetes treatment industry.
Islet Sciences, Inc. COO to Present at Metabolic Leaders Forum
GlobeNewswire - Tue Mar 24, 6:55AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced today that Chief Operating Officer, Dr. William Wilkison, will present data on remogliflozin etabonate and its efficacy and safety in the treatment of type 2 diabetes and NAFLD/NASH as well as participating in a panel discussion at the Metabolic Leaders Forum 2015 in Boston, MA on March 24th.
Differences in NASH studies make direct comparisons a bit tricky
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 9:56AM CDT
GLMD: 8.63 (+0.15), RPTP: 11.55 (+0.24), GILD: 111.00 (+1.70), LJPC: 20.66 (+0.91), CNAT: 5.70 (+0.01), SHPG: 254.71 (+0.26), MRK: 60.01 (-0.22), GALT: 2.83 (+0.07), ICPT: 313.98 (+7.75), RGDO: 1.21 (unch)
Islet Sciences, Inc. COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)
GlobeNewswire - Mon Mar 09, 7:07AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced today that Chief Operating Officer, Dr. William Wilkison, was invited to present clinical and preclinical data highlighting the unique properties of selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate, as a novel treatment for non-alcoholic steatohepatitis (NASH) and its precursor, non-alcoholic fatty liver disease (NAFLD). The data will be presented at the 50th International Liver Conference held in Vienna, Austria April 22 - 26, 2015 by the European Association for the Study of Liver (EASL).
Islet Sciences calls off merger after exclusively licensing SGLT2 inhibitor
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 9:31AM CST
Islet Sciences Engages Investment Bank as Financial Advisor
GlobeNewswire - Mon Feb 09, 7:22AM CST
Islet Sciences, Inc. (OTCQB:ISLT) ("Islet Sciences" , a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced today the engagement of Summer Street Research Partners ("Summer Street" , a leading healthcare-focused investment bank, as financial advisor.
Global Diabetic Retinopathy Therapeutics Pipeline Report H2 2014 - Analysis of 28 Companies & 44 Drug Profiles
M2 - Mon Nov 10, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc9dhb/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kowa Company, Ltd. - Antisense Therapeutics Limited - BioDiem Ltd - Regeneron Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Paloma Pharmaceuticals, Inc. - Acucela Inc. - Gene Signal International SA - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Angstrom Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Dimerix Bioscience Pty Ltd - Resolvyx Pharmaceuticals, Inc - Charlesson LLC. - MacuCLEAR, Inc. - Stelic Institute & Co. - EyeCyte, Inc. - Vascular Pharmaceuticals, Inc. - PanOptica, Inc. - EyeGene, Inc. - Targazyme, Inc. - Aprogen, Inc. - MingSight Pharmaceuticals - Bionure Farma, S.L. - Islet Sciences, Inc. - Foresee Pharmaceuticals, LLC - Biomar Microbial Technologies Drug Profiles - aflibercept (recombinant) - ripasudil - AKB-9778 - ATL-1103 - DG-3173 - emixustat hydrochloride - aganirsen - GLY-230 - EG-Mirotin - Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders - DT-23552 - RX-20001 - A-6 - P-529 - BDM-E - RTU-007 - Mesenchymal Stem Cells - PRM-167 - A-717 - MS-553 - PAN-90806 - MC-4001 - AP-202 - FP-002 - Recombinant Protein for Cancer and Diabetic Retinopathy - Cyndacel-M - VPI-2690-B - Small Molecule for Diabetic Neuropathy and Retinopathy - TZ-101 - V-1932 For more information visit http://www.researchandmarkets.com/research/sc9dhb/diabetic
ITEK: 5.85 (+0.05), REGN: 496.74 (+7.73)
Islet Sciences and BHV Announce Publication of Two Phase 2b Clinical Studies of Remogliflozin Etabonate for Treating Type 2 Diabetes
Marketwired - Thu Oct 23, 6:55AM CDT
Islet Sciences, Inc. (OTCQB: ISLT) ("Islet Sciences" , a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced today the publication of two peer-reviewed articles highlighting clinical results from completed 12-week Phase 2b studies of remogliflozin etabonate ("remogliflozin" , a selective sodium glucose transporter 2 (SGLT2) inhibitor currently being developed by Brighthaven Ventures, L.L.C. ("BHV" for type 2 diabetes and nonalcoholic steatohepatitis (NASH).
Islet Sciences, Inc. Announces Exclusive Licensing Agreement Between BHV Pharma and Libbs Farmaceutica to Develop and Commercialize SGLT2 Inhibitor Remogliflozin Etabonate
GlobeNewswire - Mon Oct 06, 7:10AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced that its merger partner, BHV Pharma, has entered into an exclusive licensing agreement for its selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate ("remogliflozin" with Libbs Farmaceutica ("Libbs" , a leading Brazilian pharmaceutical company. Libbs will have exclusive rights to develop and commercialize remogliflozin in select territories in Latin America, including Brazil.
Islet Sciences and BHV Pharma Enter Into Merger Agreement; Combined Company to be Named Avogenx, Inc.
GlobeNewswire - Wed Oct 01, 9:21AM CDT
Islet Sciences, Inc. (OTCQB:ISLT) ("Islet Sciences" , a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, and Brighthaven Ventures, L.L.C., d/b/a BHV Pharma ("BHV" , a privately held pharmaceutical company developing the SGLT2 inhibitor remogliflozin etabonate ("remogliflozin" for type 2 diabetes and non-alcoholic steatohepatitis ("NASH" , jointly announced today that, consistent with the letter of intent entered into by Islet Sciences and BHV on March 12, 2014, they have entered into a merger agreement that will combine the operations and development pipelines of the two companies. Upon closing of the acquisition of BHV, the combined organization will be named Avogenx, Inc. ("Avogenx" and will continue to operate under the leadership of the current Islet Sciences management.
Islet Sciences, Inc. Receives Notice of Allowance for U.S. Patent Covering Novel IL-12 Inhibitors
GlobeNewswire - Wed Aug 06, 7:00AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled, "Lisofylline Analogs and Methods for Use." The new patent (U.S #13/477,613) will extend coverage to include a significantly broader gamut of chemical compounds, which Islet may develop as immune-modulating drugs targeting an inflammatory pathway involved in a number important diseases, including diabetes and nonalcoholic steatohepatitis (NASH).
Islet Sciences, Inc. Announces Peer-Reviewed Publication of Study Validating Novel Diabetes Diagnostic
GlobeNewswire - Wed Jul 16, 7:23AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, announced today that its collaborators at the Yale University School of Medicine have published key data highlighting the efficacy of Islet's novel diabetes diagnostic in Endocrinology, the journal of the Endocrine Society. The study demonstrated improved detection of beta-cell loss, a key biomarker of diabetes progression, using a novel technology called droplet digital PCR (ddPCR).
Islet Sciences, Inc. Highlights Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)
PR Newswire - Mon Jun 23, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, recently presented a peer-reviewed poster highlighting the unique properties of its selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin), as a novel treatment for non-alcoholic steatohepatitis (NASH) and its precursor, non-alcoholic fatty liver disease (NAFLD). The poster was presented this past Saturday at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society, at the McCormick Place West in Chicago, IL, June 21-24.
Islet Sciences, Inc. to Present at the Joint Meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014
PR Newswire - Wed Jun 18, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, will present a peer-reviewed poster relating to its highly selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin), at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society, at the McCormick Place West in Chicago, IL, June 21-24.
Islet Sciences, Inc. Presents Positive Clinical Results for Best-in-Class SGLT2 Inhibitor at American Diabetes Association (ADA) Annual Meeting
PR Newswire - Mon Jun 16, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, presented final results from its two Phase 2b clinical studies evaluating remogliflozin etabonate (a prodrug of remogliflozin, the active inhibitor) at the 74th American Diabetes Association (ADA) Annual Scientific Sessions, showing that the differentiated sodium glucose co-transporter 2 (SGLT2) inhibitor demonstrated a potential best-in-class safety and efficacy profile, when dosed once-daily or twice-daily, respectively. Positive Phase 1 results were also presented for the company's novel once-daily biphasic formulation of remogliflozin etabonate, which achieved targeted pharmacokinetic and pharmacodynamic profiles, successfully combining the best-in-class properties of previous formulations.
Islet Sciences, Inc. to Present at American Diabetes Association (ADA)
PR Newswire - Thu Jun 12, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing novel technologies for the treatment and diagnosis of metabolic disease, announced today it will present three peer-reviewed posters relating to its differentiated sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate, at the 74th American Diabetes Association (ADA) Scientific Sessions at the Moscone Center in San Francisco, June 13-17.
Islet Sciences, Inc. Publishes Data Supporting Remogliflozin Etabonate as a Potential Treatment for NAFLD and NASH
GlobeNewswire - Mon May 04, 6:47AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, has announced publication of pre-clinical data that demonstrates remogliflozin etabonate has significant potential as a novel therapeutic for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Islet Sciences, Inc. Presented at 50th International Liver Conference
GlobeNewswire - Thu Apr 23, 11:02AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced today that Chief Operating Officer, Dr. William Wilkison presented "Remogliflozin Etabonate Reduces Insulin Resistance and Liver Function Enzymes: Role for Treatment of NASH" at the 50th International Liver Conference hosted by the European Association for the Study of Liver (EASL) in Vienna, Austria.
Islet Holdings, Inc. Continues With Pursuing Damages in Federal Court
GlobeNewswire - Thu Mar 26, 7:11AM CDT
Islet Holdings, Inc. (OTC:ISHI) ("the Company"
previously announced that in August 2012, the Company and its subsidiary filed a complaint in Federal District Court for the District of Utah against Islet Sciences, Inc., a publicly-held company trading under the symbol "ISLT", and several individuals intimately involved with Islet Sciences. The complaint is related to the Company's prior work and development in the type 1 diabetes treatment industry. Islet Sciences, Inc. COO to Present at Metabolic Leaders Forum
GlobeNewswire - Tue Mar 24, 6:55AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced today that Chief Operating Officer, Dr. William Wilkison, will present data on remogliflozin etabonate and its efficacy and safety in the treatment of type 2 diabetes and NAFLD/NASH as well as participating in a panel discussion at the Metabolic Leaders Forum 2015 in Boston, MA on March 24th.
Differences in NASH studies make direct comparisons a bit tricky
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 9:56AM CDT
GLMD: 8.63 (+0.15), RPTP: 11.55 (+0.24), GILD: 111.00 (+1.70), LJPC: 20.66 (+0.91), CNAT: 5.70 (+0.01), SHPG: 254.71 (+0.26), MRK: 60.01 (-0.22), GALT: 2.83 (+0.07), ICPT: 313.98 (+7.75), RGDO: 1.21 (unch)
Islet Sciences, Inc. COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)
GlobeNewswire - Mon Mar 09, 7:07AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced today that Chief Operating Officer, Dr. William Wilkison, was invited to present clinical and preclinical data highlighting the unique properties of selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate, as a novel treatment for non-alcoholic steatohepatitis (NASH) and its precursor, non-alcoholic fatty liver disease (NAFLD). The data will be presented at the 50th International Liver Conference held in Vienna, Austria April 22 - 26, 2015 by the European Association for the Study of Liver (EASL).
Islet Sciences calls off merger after exclusively licensing SGLT2 inhibitor
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 9:31AM CST
Islet Sciences Engages Investment Bank as Financial Advisor
GlobeNewswire - Mon Feb 09, 7:22AM CST
Islet Sciences, Inc. (OTCQB:ISLT) ("Islet Sciences"
, a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced today the engagement of Summer Street Research Partners ("Summer Street" , a leading healthcare-focused investment bank, as financial advisor. Global Diabetic Retinopathy Therapeutics Pipeline Report H2 2014 - Analysis of 28 Companies & 44 Drug Profiles
M2 - Mon Nov 10, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc9dhb/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kowa Company, Ltd. - Antisense Therapeutics Limited - BioDiem Ltd - Regeneron Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Paloma Pharmaceuticals, Inc. - Acucela Inc. - Gene Signal International SA - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Angstrom Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Dimerix Bioscience Pty Ltd - Resolvyx Pharmaceuticals, Inc - Charlesson LLC. - MacuCLEAR, Inc. - Stelic Institute & Co. - EyeCyte, Inc. - Vascular Pharmaceuticals, Inc. - PanOptica, Inc. - EyeGene, Inc. - Targazyme, Inc. - Aprogen, Inc. - MingSight Pharmaceuticals - Bionure Farma, S.L. - Islet Sciences, Inc. - Foresee Pharmaceuticals, LLC - Biomar Microbial Technologies Drug Profiles - aflibercept (recombinant) - ripasudil - AKB-9778 - ATL-1103 - DG-3173 - emixustat hydrochloride - aganirsen - GLY-230 - EG-Mirotin - Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders - DT-23552 - RX-20001 - A-6 - P-529 - BDM-E - RTU-007 - Mesenchymal Stem Cells - PRM-167 - A-717 - MS-553 - PAN-90806 - MC-4001 - AP-202 - FP-002 - Recombinant Protein for Cancer and Diabetic Retinopathy - Cyndacel-M - VPI-2690-B - Small Molecule for Diabetic Neuropathy and Retinopathy - TZ-101 - V-1932 For more information visit http://www.researchandmarkets.com/research/sc9dhb/diabetic
ITEK: 5.85 (+0.05), REGN: 496.74 (+7.73)
Islet Sciences and BHV Announce Publication of Two Phase 2b Clinical Studies of Remogliflozin Etabonate for Treating Type 2 Diabetes
Marketwired - Thu Oct 23, 6:55AM CDT
Islet Sciences, Inc. (OTCQB: ISLT) ("Islet Sciences"
, a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced today the publication of two peer-reviewed articles highlighting clinical results from completed 12-week Phase 2b studies of remogliflozin etabonate ("remogliflozin" , a selective sodium glucose transporter 2 (SGLT2) inhibitor currently being developed by Brighthaven Ventures, L.L.C. ("BHV" for type 2 diabetes and nonalcoholic steatohepatitis (NASH). Islet Sciences, Inc. Announces Exclusive Licensing Agreement Between BHV Pharma and Libbs Farmaceutica to Develop and Commercialize SGLT2 Inhibitor Remogliflozin Etabonate
GlobeNewswire - Mon Oct 06, 7:10AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced that its merger partner, BHV Pharma, has entered into an exclusive licensing agreement for its selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate ("remogliflozin"
with Libbs Farmaceutica ("Libbs" , a leading Brazilian pharmaceutical company. Libbs will have exclusive rights to develop and commercialize remogliflozin in select territories in Latin America, including Brazil. Islet Sciences and BHV Pharma Enter Into Merger Agreement; Combined Company to be Named Avogenx, Inc.
GlobeNewswire - Wed Oct 01, 9:21AM CDT
Islet Sciences, Inc. (OTCQB:ISLT) ("Islet Sciences"
, a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, and Brighthaven Ventures, L.L.C., d/b/a BHV Pharma ("BHV" , a privately held pharmaceutical company developing the SGLT2 inhibitor remogliflozin etabonate ("remogliflozin" for type 2 diabetes and non-alcoholic steatohepatitis ("NASH" , jointly announced today that, consistent with the letter of intent entered into by Islet Sciences and BHV on March 12, 2014, they have entered into a merger agreement that will combine the operations and development pipelines of the two companies. Upon closing of the acquisition of BHV, the combined organization will be named Avogenx, Inc. ("Avogenx" and will continue to operate under the leadership of the current Islet Sciences management. Islet Sciences, Inc. Receives Notice of Allowance for U.S. Patent Covering Novel IL-12 Inhibitors
GlobeNewswire - Wed Aug 06, 7:00AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled, "Lisofylline Analogs and Methods for Use." The new patent (U.S #13/477,613) will extend coverage to include a significantly broader gamut of chemical compounds, which Islet may develop as immune-modulating drugs targeting an inflammatory pathway involved in a number important diseases, including diabetes and nonalcoholic steatohepatitis (NASH).
Islet Sciences, Inc. Announces Peer-Reviewed Publication of Study Validating Novel Diabetes Diagnostic
GlobeNewswire - Wed Jul 16, 7:23AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, announced today that its collaborators at the Yale University School of Medicine have published key data highlighting the efficacy of Islet's novel diabetes diagnostic in Endocrinology, the journal of the Endocrine Society. The study demonstrated improved detection of beta-cell loss, a key biomarker of diabetes progression, using a novel technology called droplet digital PCR (ddPCR).
Islet Sciences, Inc. Highlights Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)
PR Newswire - Mon Jun 23, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, recently presented a peer-reviewed poster highlighting the unique properties of its selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin), as a novel treatment for non-alcoholic steatohepatitis (NASH) and its precursor, non-alcoholic fatty liver disease (NAFLD). The poster was presented this past Saturday at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society, at the McCormick Place West in Chicago, IL, June 21-24.
Islet Sciences, Inc. to Present at the Joint Meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014
PR Newswire - Wed Jun 18, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, will present a peer-reviewed poster relating to its highly selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin), at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society, at the McCormick Place West in Chicago, IL, June 21-24.
Islet Sciences, Inc. Presents Positive Clinical Results for Best-in-Class SGLT2 Inhibitor at American Diabetes Association (ADA) Annual Meeting
PR Newswire - Mon Jun 16, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, presented final results from its two Phase 2b clinical studies evaluating remogliflozin etabonate (a prodrug of remogliflozin, the active inhibitor) at the 74th American Diabetes Association (ADA) Annual Scientific Sessions, showing that the differentiated sodium glucose co-transporter 2 (SGLT2) inhibitor demonstrated a potential best-in-class safety and efficacy profile, when dosed once-daily or twice-daily, respectively. Positive Phase 1 results were also presented for the company's novel once-daily biphasic formulation of remogliflozin etabonate, which achieved targeted pharmacokinetic and pharmacodynamic profiles, successfully combining the best-in-class properties of previous formulations.
Islet Sciences, Inc. to Present at American Diabetes Association (ADA)
PR Newswire - Thu Jun 12, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing novel technologies for the treatment and diagnosis of metabolic disease, announced today it will present three peer-reviewed posters relating to its differentiated sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate, at the 74th American Diabetes Association (ADA) Scientific Sessions at the Moscone Center in San Francisco, June 13-17.
